ERBB2 and prostate carcinoma: Ipatasertib, an Akt inhibitor, has demonstrated good tolerability and safety when combined with chemotherapy or hormonal treatments for prostate cancer, though its effect on renal cell carcinoma remains unexplored [90, 91] Lapatinib, an EGFR/HER-2 tyrosine kinase inhibitor, exhibits better overall tolerance compared to hormonal therapy among advanced RCC patients who have progressed following initial cytokine treatment.